Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KER-012 in chronic heart failure
ACTRN12623001290684Phase 2Withdrawn
- Sponsor
- Keros Therapeutics
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cibotercept in chronic heart failure (CHF) (2 cohorts), sponsored by Keros Therapeutics. Primary endpoints: Treatment-emergent adverse events and discontinuations, Changes in laboratory values, vital signs, and electrocardiogram and 1 more. Planned start Jun 2024; status: withdrawn.
02
Drugs
cibotercept
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on ACTRN12623001290684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001290684.